sellWeak cluster of 610b5-1 plan
Kintz Samuel sold $28k of ELVN
PRESIDENT AND CEO at Enliven Therapeutics, Inc.. 924 shares at an average of $30.00, traded Oct 18, 2024, filed Oct 22, 2024.
Warning score
25Value
$28k
924 shares
Holdings after
1,002,892
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-025503, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 18, 2024 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -924 | $30.00 | $28k | 1,002,892 | Oct 22, 2024 |
Related signals
Other insiders at Enliven Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 15Weak | sell 310b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $69k | 3,250 | |
| 2Weak | sell 310b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $23k | 1,000 | |
| 23Weak | sell 410b5-1 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | $258k | 12,500 | |
| 33Weak | sell 410b5-1 | ELVN Enliven Therapeutics, Inc. | Kintz Samuel PRESIDENT AND CEO | $260k | 12,500 | |
| 26Weak | sell 410b5-1 | ELVN Enliven Therapeutics, Inc. | Patel Anish CHIEF OPERATING OFFICER | $143k | 6,667 | |
| 8Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $66k | 3,250 | |
| 19Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | Patel Anish CHIEF OPERATING OFFICER | $146k | 6,667 | |
| 0Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $23k | 1,000 | |
| 8Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $70k | 3,250 | |
| 34Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | Patel Anish CHIEF OPERATING OFFICER | $686k | 28,367 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.